Valeant Pharma (VRX) & Salix Pharma to Stay Outstanding Litigation and Extend 30-Month Stay Regarding Actavis' ANDA for Xifaxan (Rifaximin)
May 17, 2017 7:08 AM
Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Actavis Laboratories, Inc., at ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
